Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A new species of amyloid peptide

26.11.2004


Scientists have identified a new, longer species of amyloid â-peptide that has the potential to be a new target for the treatment of Alzheimer’s disease. The research appears as the "Paper of the Week" in the December 3 issue of the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal.



One of the characteristic features of Alzheimer’s disease is the deposition of amyloid â-peptides in the brain. These amyloid â-peptides are derived from a large amyloid precursor protein through a series of cleavage events. Under normal conditions, cleavage first by á-secretase and then by ã-secretase results in a soluble ectodomain, a short peptide called p3, and an intracellular C-terminal domain, none of which are amyloidogenic. Alternatively, amyloid precursor protein can be processed by the enzymes â-secretase and ã-secretase to produce a soluble ectodomain along with the full-length amyloidogenic amyloid â-peptide and the intracellular C-terminal domain.

Although amyloid precursor protein is found in many cells, its normal biological function is not well understood. "It has been suggested that amyloid precursor protein may function as a receptor or growth factor precursor," notes Dr. Xuemin Xu of The University of Tennessee. "Recent studies also suggest that the intracellular C-terminal domain of the amyloid precursor protein may function as a transcription factor."


While the exact pathogenic role of amyloid â-peptide in Alzheimer’s disease has not yet been definitely established, accumulating evidence supports the hypothesis that amyloid â-peptide production and deposition in the brain could be a causative event in Alzheimer’s disease. Dr. Xu explains that the literature indicates amyloid â-peptide itself could be toxic to synapses and the accumulation of amyloid â-peptide could initiate a series of events contributing to cell death, including activation of cell death programs, oxidation of lipids and disruption of cell membranes, an inflammatory response, and possibly neurofibrillary tangle formation, which is a close correlate of neuron loss. Therefore, the problem of production, accumulation, and clearance of amyloid â-peptide in the brain emerges as one of the possible rational approaches for the treatment of Alzheimer’s disease.

Generally, amyloid â-peptides are around 39-43 amino acid long. Studies have shown that the longer amyloid â-peptides are more amyloidogenic and more pathogenic than the shorter ones. Now, Dr. Xu and his colleagues have discovered a new species of amyloid â-peptide that is 46 amino acids long, called Aâ46. This Aâ46 peptide is produced by ã-secretase at a novel cleavage site, the æ-site. This site also happens to be the site of a mutation found in early-onset familial Alzheimer’s disease called the APP717 or London mutation.

"Another well characterized Alzheimer’s disease-linked amyloid precursor protein mutation, the Swedish mutation, also occurs at a major cleavage site, the â-cleavage site at the N-terminus of amyloid â-peptide," adds Dr. Xu. "Studies have shown that Swedish mutation at the â-cleavage site makes the amyloid precursor protein more susceptible to â-secretase activity. The finding that æ-cleavage site is the APP717 mutation site suggests that the APP717 mutation may cause enhanced production of the longer amyloid â-peptide, Aâ42, by influencing the æ-cleavage. Therefore, this finding may open a new avenue for studying the mechanism by which APP717 mutations cause enhanced production of the longer amyloid â-peptide."

Dr. Xu and his colleagues also discovered that ã-secretase cleavage at the new æ-site is specifically inhibited by compounds known as transition state analogs, but is less affected by compounds known as non-transition state inhibitors. Specifically, some of these inhibitors, which were previously known to inhibit the formation of secreted amyloid â-peptides, were found to cause an intracellular accumulation of an even longer amyloid â-peptide species, Aâ46. "These novel findings provide information important for the strategy of prevention and treatment of Alzheimer’s disease, aimed at the design of ã-secretase inhibitors," concludes Dr. Xu. "Since amyloid â-peptide is produced by the sequential actions of â- and ã-secretases, inhibition of these secretases to reduce the production of amyloid â-peptide is believed to be one of the more promising avenues of treatment of the disease. To date, more than one dozen ã-secretase inhibitors have been developed or identified."

Nicole Kresge | EurekAlert!
Further information:
http://www.asbmb.org
http://www.jbc.org

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>